Work

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

Year: 2009

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet

DOI: 10.1016/s0140-6736(09)60250-6

Authors: David M Reid, Jean-Pierre Devogelaer, Kenneth Saag, Christian Roux, Chak-Sing Lau, Jean-Yves Reginster, Philemon Papanastasiou, Alberto Ferreira, Florian Hartl, Taiwo Fashola, Peter Mesenbrink, Philip N Sambrook

Institutions: University of Aberdeen, UCLouvain, University of Alabama at Birmingham, Université Paris Descartes, University of Dundee, University of Liège, Novartis (Switzerland), F. Hoffmann-La Roche AG, The University of Sydney

Language: English

Topic: Bone health and osteoporosis research

Subfield: Orthopedics and Sports Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institute for Health and Care Research

Award: NIHR Senior Investigator Award

OpenAlex ID: W2095741166

FWCI: 62.23

Cites: 36

Cited by: 524

Related to: 10